Catch­ing up with Keytru­da, Re­gen­eron scores front­line NSCLC ap­proval for Lib­tayo/chemo com­bo

Re­gen­eron’s Lib­tayo has made it in­to the ex­clu­sive club of PD-(L) in­hibitors ap­proved, in com­bi­na­tion with chemother­a­py, as a front­line treat­ment for a broad swath …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER